Leigh Syndrome Clinical Trial
Official title:
The International Registry for Leigh Syndrome
The purpose of this study is to develop a database containing clinical and laboratory information for patients with Leigh syndrome. The goal is to provide a greater understanding of Leigh syndrome allowing further characterization of this disease.
Leigh syndrome, also known as juvenile sub-acute necrotizing encephalopathy, is a progressive neurodegenerative disorder associated with dysfunction of mitochondrial oxidative phosphorylation (OXPHOS). First described in 1951 by British neuropsychiatrist Archibald Denis Leigh, the condition has evolved from a post mortem diagnosis to a clinical entity with characteristic radiologic and laboratory findings. Leigh syndrome is a rare and heterogeneous disease, finding a substantial number of patients to study is difficult. The lack of natural history data in Leigh syndrome and the small number of patients included in clinical reports thus far has limited the ability to fully comprehend the progression of this disease and assess prognostic factors. A Leigh syndrome database will help improve our understanding of this rare disease leading to an improved ability to predict outcomes and/or improve treatment paradigms. Collecting natural history data on Leigh syndrome and integrating this information into a database will be useful in understanding the course of the disease and identifying trends. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04378075 -
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
|
Phase 2/Phase 3 | |
Completed |
NCT01721733 -
Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome
|
Phase 2 | |
Withdrawn |
NCT05277363 -
A Study of the Natural Course of SURF1 Deficiency
|
||
Completed |
NCT02544217 -
A Dose-escalating Clinical Trial With KH176
|
Phase 1 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Completed |
NCT02352896 -
Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome
|
Phase 2 | |
Recruiting |
NCT05554835 -
Global Registry and Natural History Study for Mitochondrial Disorders
|
||
Withdrawn |
NCT03747328 -
ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
|
Phase 2 |